Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.
about
Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigmTherapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advancesLung cancer: a classic example of tumor escape and progression while providing opportunities for immunological interventionAdvances in the understanding of cancer immunotherapyEndpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesImmunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implicationsHumoral response to a viral glycan correlates with survival on PROSTVAC-VFPreclinical and clinical development of DNA vaccines for prostate cancer.Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells.HCA519/TPX2: a potential T-cell tumor-associated antigen for human hepatocellular carcinomaEmerging proteomics biomarkers and prostate cancer burden in Africa.Circulating tumor cells as biomarkers in prostate cancer.A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccineAsymptotic dynamics of some t-periodic one-dimensional model with application to prostate cancer immunotherapy.Prostate cancer - a biomarker perspective.Future perspectives of prostate cancer therapy.A changing landscape in castration-resistant prostate cancer treatmentCombination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity.The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer.Novel therapies for the treatment of advanced prostate cancer.Cancer vaccines: Looking to the future.Therapeutic vaccines: the ultimate personalized therapy?Immunotherapy and immune evasion in prostate cancer.TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancer.Outlining novel scenarios for improved therapeutic cancer vaccines: the PANVAC paradigm.Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era.Cancer immunotherapy: a paradigm shift for prostate cancer treatment.The evolving role of immunotherapy in prostate cancer.Optimal management of recurrent prostate cancer in older patients.Ipilimumab in prostate cancer.Optimal therapy sequencing in metastatic castration-resistant prostate cancer.Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies.Therapeutic cancer vaccines: a long and winding road to success.Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugsPROSTVAC® targeted immunotherapy candidate for prostate cancer.
P2860
Q26747699-E8AAD80A-4021-4BE5-BCE6-EC2219155FF9Q26827475-AE0F2DBB-6132-4AD8-B729-552F59ABE27EQ26850218-B3E541E1-BE0D-4A5C-8EE7-907738AC09C2Q27000706-DBE693EE-DC97-45F8-889D-558FFA14C974Q27008070-12F94DB7-6BB6-4EB7-BE1B-A2BC7AF64ED0Q33621393-F985FBFF-AACA-48F1-B986-9B231A0396BFQ33674367-8622F5CB-A1C1-4BAE-9CC0-AEBFEF91E17BQ33740811-AAEE6E59-E252-4C58-A59D-8180BE79E043Q33768093-ADD9D884-4E61-4CE9-A662-8DE6E3952ABBQ33779140-85F402E4-3EC2-4B9C-832E-C72687956F95Q33914221-C3D61086-E534-4ACC-8AAE-25F7AB3B3406Q34193303-48073217-58ED-4BFD-A45A-695B6EB70B76Q34289239-EF197E84-D0F7-4FD3-9AFE-06CFB904075AQ34321844-AFA8CA48-B599-4E71-861E-28E0545CCD23Q35757242-CFBB9DF5-F795-457D-BA5F-6C1B9102CD89Q35929337-4A46B594-FB6C-40DF-A7A3-C4A2CB38A405Q35992814-61392B7C-F7C6-469F-91A9-045FE928B9A6Q36076453-223E97C4-437E-4BA1-9528-E1F67C5D1E04Q36101308-F174366D-64FF-469B-9F01-7147F49F7060Q36388538-03D843F8-D7A5-4295-AF83-923F60A6C4D6Q36625406-7454ADCB-8DFB-4AE3-80FD-A359B3A9C90AQ36665708-AB629016-18FA-41C6-B106-4F8199AA3B59Q36866158-00B2EB19-48A9-4DA6-8415-FF002529B256Q36888016-B9563D27-8A0C-482B-AEB8-2160794EFC2EQ37061769-BAEF1895-880A-44EB-BC80-87951F31EBC1Q37224581-BA747880-EFB7-4352-9E4C-6D71C15798BFQ37970682-C28785FD-40F3-4A3F-AFEF-3BCC0E0887EBQ37988725-08B8BEE9-DD2C-4B63-8D2D-DA060DC9FC5AQ37989569-777ECD13-502E-4D45-BF1D-C1D9733A056CQ37989571-75C93582-6983-4268-9908-83D91E1A765AQ38013964-8E070853-7DD1-47FA-93DE-03289FC5BCC6Q38037488-AC1F5C90-D5C9-4F16-82C0-F1E4E7E530D4Q38058455-E09D03DF-BCD5-4899-AC86-079B71AEFE9DQ38069640-BE70EF45-31CC-4586-BDBA-0D9BF34CD409Q38097373-550DE33A-BD2C-4E34-9184-B507DDEDA02FQ38159805-D86915AC-1604-4E67-BAB8-142CA53CB424Q38162261-6E60D8BC-5033-4B5A-AD4D-DC767A3F3A26Q38162290-983D9195-41ED-4723-89AA-02F5E7C5FC28Q38206520-B6FE14EE-EF19-4AF2-9E8E-60521E0923D1Q38206815-E823C251-561B-4FF6-9C6E-B261BA63A617
P2860
Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Immunotherapy for prostate can ...... nd areas for further research.
@ast
Immunotherapy for prostate can ...... nd areas for further research.
@en
type
label
Immunotherapy for prostate can ...... nd areas for further research.
@ast
Immunotherapy for prostate can ...... nd areas for further research.
@en
prefLabel
Immunotherapy for prostate can ...... nd areas for further research.
@ast
Immunotherapy for prostate can ...... nd areas for further research.
@en
P2860
P1476
Immunotherapy for prostate can ...... nd areas for further research.
@en
P2093
Charles G Drake
James L Gulley
P2860
P304
P356
10.1158/1078-0432.CCR-10-2656
P407
P577
2011-06-01T00:00:00Z